Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,902 | 14,969 | 16,506 | 20,054 | 18,249 |
| TOTAL | $13,089 | $19,788 | $21,756 | $25,795 | $24,801 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 21 | 21 | 24 | 21 | 23 |
| TOTAL | $21 | $21 | $24 | $21 | $23 |
| Total Assets | $13,110 | $19,809 | $21,780 | $25,816 | $24,824 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,631 | 2,205 | 3,776 | 2,076 | 2,168 |
| Accrued Expenses | 5,617 | 6,898 | 6,074 | 5,769 | 5,818 |
| Other current liabilities | 10 | 822 | 25 | 37 | 56 |
| TOTAL | $19,327 | $22,617 | $22,064 | $15,585 | $8,042 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | 2,822 | N/A |
| TOTAL | $N/A | $N/A | $N/A | $2,822 | $N/A |
| Total Liabilities | $19,327 | $22,617 | $22,064 | $18,407 | $8,042 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8,392 | 8,170 | 7,031 | 7,156 | 6,764 |
| Common Shares | 84 | 80 | 70 | 67 | 68 |
| Retained earnings | -248,815 | -242,753 | -234,036 | -222,997 | -212,756 |
| Other shareholders' equity | -19 | -22 | 106 | 0 | 0 |
| TOTAL | $-6,217 | $-2,808 | $-284 | $7,409 | $16,782 |
| Total Liabilities And Equity | $13,110 | $19,809 | $21,780 | $25,816 | $24,824 |